BC
ATRA icon

Birchview Capital’s Atara Biotherapeutics ATRA Stock Holding History

Birchview Capital’s Portfolio ATRA Stock Details ATRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-22,000
Closed -$131K – 73
2025
Q1 		$131K Hold
22,000
– – 0.11% 60
2024
Q4 		$293K Buy
+22,000
New +$232K 0.24% 48
2019
Q3 		– Sell
-800
Closed -$402K – 52
2019
Q2 		$402K Sell
800
-160
-17% -$113K 0.24% 36
2019
Q1 		$954K Sell
960
-400
-29% -$372K 0.6% 15
2018
Q4 		$1.18M Hold
1,360
– – 1.12% 9
2018
Q3 		$1.41M Hold
1,360
– – 0.91% 12
2018
Q2 		$1.25M Buy
1,360
+440
+48% +$473K 0.85% 14
2018
Q1 		$897K Buy
+920
New +$838K 0.59% 15

Other funds holding ATRA

EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
SCA
STALEY CAPITAL ADVISERS Pittsburgh, Pennsylvania $2.57B AUM 26.96% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Birchview Capital's ATRA Position: Q2 2025 in Review

Birchview Capital sold out of Atara Biotherapeutics (ATRA) in Q2 2025, closing a stake of 22,000 shares — an estimated $131K sold.

Birchview Capital first reported a position in ATRA in Q1 2018 and held it in 8 quarters. The position peaked at $1.41M in Q3 2018. 32 funds tracked by Wall St. Rank hold ATRA as of Q2 2025.

  • Birchview Capital reported no remaining Atara Biotherapeutics position as of Q2 2025 after selling out during the quarter.
  • Birchview Capital sold 22,000 Atara Biotherapeutics shares in Q2 2025, an estimated $131K.
  • Birchview Capital first reported a position in Atara Biotherapeutics in Q1 2018 and held it in 8 quarters.
  • Birchview Capital's Atara Biotherapeutics position peaked at $1.41M in Q3 2018.
  • 32 funds tracked by Wall St. Rank held Atara Biotherapeutics as of Q2 2025.

Based on Birchview Capital's 13F filing for Q2 2025, filed 14 Aug 2025.